The article discusses the ongoing lack of compensation for women harmed by pelvic mesh implants and families affected by the epilepsy drug valproate, despite plans for financial redress being outlined by England's patient safety commissioner two years ago. The article suggests uncertainty and delays in providing the promised compensation.
Mesh and valproate: Still no compensation, two years after report
Informational, non-clinical synthesis informed by published research. Not a clinical guideline or medical advice. May contain errors or editorial interpretation. Consult the original source and your physician.
